To further confirm whether VANGL2 alleviates DSS-induced colitis by affecting NLRP3 inflammasome activation, we inhibited NLRP3 inflammasome by MCC950 during DSS treatment in vivo and observed that the survival rate of Vangl2ΔM/ΔM mice was lower than that of WT mice, while MCC950 treatment effectively improved the survival rate of Vangl2ΔM/ΔM mice and was comparable to WT mice (Fig 7A). Here, VANGL2 is linked to colitis.